NEW YORK, Jan. 13-EGeen International and Prediction Sciences will collaborate to study the pharmacogenetics of Paxil, the two companies said today.
EGeen will provide the clinical data and Prediction Sciences will supply bioinformatics expertise to determine the genetic basis of patient response to this commonly prescribed anti-depressant.
EGeen, based in Redwood City, Calif., has exclusive commercial rights to data from the Estonian Gene Bank, a national database collecting genetic and clinical information from patients throughout Estonia. The company uses this database for drug and diagnostic discovery and for pharmacogenomic studies.
Prediction Sciences is a San Diego, Calif.-based private company developing bioinformatics for pharmacogenetic applications.
Earlier this year, the two companies struck a similar partnershipto study the pharmacogenetics of Celexa, another treatment for depression. Prediction Sciences hopes to create a comprehensive pharmacogenetic diagnostic panel to guide in the prescription of anti-depressants.